European Myeloma Network Sequential Phase I / Phase II Trial on RIC Allogeneic Transplantation: an Optimized Program for High Risk Relapsed Patients

Trial Profile

European Myeloma Network Sequential Phase I / Phase II Trial on RIC Allogeneic Transplantation: an Optimized Program for High Risk Relapsed Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
  • Indications Graft-versus-host disease; Haematological malignancies; Multiple myeloma
  • Focus Adverse reactions
  • Acronyms EMN-alloRIC
  • Most Recent Events

    • 05 Jul 2017 Status changed from recruiting to completed.
    • 29 Nov 2016 Planned End Date changed from 1 May 2016 to 1 Jun 2017.
    • 29 Nov 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top